Multicentral Retrospective Analysis of Venetoclax-Based Treatments in AML and MDS: A Real-World Study by the Turkish Hematology Network Group

Basit Öğe Kaydı
dc.authoridAcar, Ibrahim halil/0000-0002-8657-1407
dc.authoridIpek, Yildiz/0000-0003-2952-2286
dc.authoridSENTURK YIKILMAZ, AYSUN/0000-0001-5281-5955
dc.authoridKars, Taha Ulutan/0000-0003-4013-4647
dc.authoridUysal, Ayse/0000-0002-5581-8104
dc.contributor.authorAcar, Ibrahim Halil
dc.contributor.authorAslaner Ak, Muzeyyen
dc.contributor.authorAkyol, Gulsah
dc.contributor.authorKars, Taha Ulutan
dc.contributor.authorIpek, Yildiz
dc.contributor.authorUysal, Ayse
dc.contributor.authorAtalay, Figen
dc.date.accessioned2025-03-26T17:34:45Z
dc.date.available2025-03-26T17:34:45Z
dc.date.issued2024
dc.departmentİstanbul Esenyurt Üniversitesi
dc.description.abstractBackground and Objectives: Acute myeloid leukemia and myelodysplastic syndrome are both clonal hematologic malignancies that primarily affect older adults. Current treatments for AML/MDS are both limited in number and efficacy. This study aims to evaluate venetoclax-based therapies in AML/MDS, focusing on overall survival and recurrence-free survival rates, and to expand real-world data on its use. Materials and Methods: Clinical and laboratory data on patients with AML/MDS aged 18 >= treated with venetoclax between January 2019 and July 2022 were included. Survival analysis was calculated based on the period from 2019 to December 2023. Results: A total of 161 AML and 40 patients with MDS were included. The median age was 63.53 +/- 15.30 years for AML and 70.12 +/- 10.21 years for MDS. In both groups, over 55% are male. A total of 77.6% of patients with AML and 75% of patients with MDS received treatment prior to venetoclax. Venetoclax was administered in combination with azacitidine to 84.5% of AML and 67.5% of MDS. The relapse rate in AML is approximately 15%. Overall, the 2-year survival rate is 46% and 18.73 months. The overall CR/CRi rate for patients with AML is 49.1%, while for patients with MDS, it is 50%. The 2-year survival rate for patients with MDS is 52.7%. The 2-year RFS rate was 75.5% for AML and 90.9% for MDS. The relapse rate in AML is approximately 15%. The percentage of adverse events leading to treatment discontinuation among those with grade 3-4 toxicity is low; 26.7% for AML (n = 43) and 15% for MDS (n = 6). Conclusions: Our real-world data demonstrate that venetoclax has the potential to improve overall survival rates when used in combination with HMAs and supports its use in patients with AML/MDS.
dc.description.sponsorshipHematology Specialty Society (Turkiye); Hematology Specialty Society
dc.description.sponsorshipThis study was supported by the Hematology Specialty Society (Turkiye).
dc.identifier.doi10.3390/medicina60101623
dc.identifier.issn1010-660X
dc.identifier.issn1648-9144
dc.identifier.issue10
dc.identifier.pmid39459410
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.3390/medicina60101623
dc.identifier.urihttps://hdl.handle.net/20.500.14704/885
dc.identifier.volume60
dc.identifier.wosWOS:001342801400001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMDPI
dc.relation.ispartofMedicina-Lithuania
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250326
dc.subjectacute myeloid leukemia; myelodysplastic syndrome; venetoclax; treatment outcome; malignancy
dc.titleMulticentral Retrospective Analysis of Venetoclax-Based Treatments in AML and MDS: A Real-World Study by the Turkish Hematology Network Group
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu